Researchof multidrug resistant Acinetobacter

This study reports the dissemination of multidrug-resistant (MDR) OXA-23-producing Acinetobacter baumannii clones in hospitals in Antananarivo, Madagascar. A total of 53 carbapenem-resistant A. baumannii isolates were obtained from September 2006 to March 2009 in five hospitals. These resistant strains represent 44% of all A. baumannii isolates. The double disk synergy test was performed to screen for production of metallo-beta-lactamases. Polymerase chain reaction (PCR) and DNA sequencing were performed for the detection of bla(AmpC), bla(OXA-51),bla(OXA-23), bla(OXA-24), bla(IMP), bla(VIM). The presence of the insertion sequence ISAba1 relative to blaOXA-23 and blaOXA-51 was assessed by PCR. Isolates were typed by Rep-PCR. All the isolates were MDR and produced the OXA-23 carbapenemase, which was confirmed by sequencing. PCR analysis for AmpC and OXA-51 gave positive results for all strains studied. No isolates produced metallo-beta-lactamases. In all isolates ISAba1 laid upstream of blaOXA-23. The A. baumannii isolates were separated into two genotypes; genotype A had a higher prevalence (41 strains) than genotype B (12 strains). Genotype A was present in four hospitals, whilst genotype B had spread in two hospitals. The high frequency of MDR OXA-23-producing A. baumannii in various hospitals in Antananarivo is curious since carbapenems are not available in Madagascar, but it emphasises the need for infection control procedures and strict adherence to them to prevent the spread of these resistant organisms in Antananarivo and also the need to control the use of carbapenems in the future.

[1]  Qing Yang,et al.  Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. , 2010, The Journal of antimicrobial chemotherapy.

[2]  Hee-Young Yang,et al.  Outbreaks of Imipenem Resistant Acinetobacter Baumannii Producing OXA-23 β-Lactamase in a Tertiary Care Hospital in Korea , 2009, Yonsei medical journal.

[3]  L. Dijkshoorn,et al.  OXA-23-type imipenem resistance in Acinetobacter baumannii in Hong Kong. , 2009, International journal of antimicrobial agents.

[4]  G. Peirano,et al.  Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. , 2009, International journal of antimicrobial agents.

[5]  M. Morillon,et al.  Role of contaminated aspiration tubes in nosocomial outbreak of Klebsiella pneumoniae producing SHV-2 and CTX-M-15 extended-spectrum beta-lactamases. , 2009, The Journal of hospital infection.

[6]  Nitsara Boonkerd,et al.  Carbapenem-resistant Acinetobacter baumannii producing OXA-23 in Thailand. , 2009, Japanese journal of infectious diseases.

[7]  P. Nordmann,et al.  Dissemination of OXA-23-producing and carbapenem-resistant Acinetobacter baumannii in a University Hospital in Tunisia. , 2008, Microbial drug resistance.

[8]  M. Castanheira,et al.  Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. , 2008, Journal of medical microbiology.

[9]  P. Nordmann,et al.  Carbapenem-Resistant Acinetobacter baumannii Isolates Expressing the blaOXA-23 Gene Associated with ISAba4 in Belgium , 2008, Antimicrobial Agents and Chemotherapy.

[10]  P. Higgins,et al.  Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  C. Vay,et al.  Polyclonal spread of bla(OXA-23) and bla(OXA-58) in Acinetobacter baumannii isolates from Argentina. , 2008, Journal of infection in developing countries.

[12]  P. Nordmann,et al.  Acinetobacter radioresistens as a Silent Source of Carbapenem Resistance for Acinetobacter spp , 2008, Antimicrobial Agents and Chemotherapy.

[13]  Shu-sen Zheng,et al.  Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. , 2007, Journal of medical microbiology.

[14]  J. Quinn,et al.  Dissemination of Acinetobacter baumannii Clones with OXA-23 Carbapenemase in Colombian Hospitals , 2007, Antimicrobial Agents and Chemotherapy.

[15]  L. Hsu,et al.  IMP-4 and OXA β-lactamases in Acinetobacter baumannii from Singapore , 2007 .

[16]  Y. An,et al.  Outbreaks of imipenem-resistant Acinetobacter baumannii producing carbapenemases in Korea. , 2006, Journal of microbiology.

[17]  F. Budak,et al.  High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. , 2006, The Journal of antimicrobial chemotherapy.

[18]  N. Høiby,et al.  OXA-type carbapenemases. , 2006, The Journal of antimicrobial chemotherapy.

[19]  Jonathan R Edwards,et al.  Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  P. Nordmann,et al.  Outbreak of Carbapenem-Resistant Acinetobacter baumannii Producing the Carbapenemase OXA-23 in a Tertiary Care Hospital of Papeete, French Polynesia , 2005, Journal of Clinical Microbiology.

[21]  H. Segal,et al.  Use of Etest MBL strips for the detection of carbapenemases in Acinetobacter baumannii. , 2005, The Journal of antimicrobial chemotherapy.

[22]  Jung Hun Lee,et al.  Investigation of a Nosocomial Outbreak of Imipenem-Resistant Acinetobacter baumannii Producing the OXA-23 β-Lactamase in Korea , 2005, Journal of Clinical Microbiology.

[23]  Y. Carmeli,et al.  Multidrug-Resistant Acinetobacter baumannii , 2005, Emerging infectious diseases.

[24]  R. Gaynes,et al.  NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE S. OVERVIEW OF NOSOCOMIAL INFECTIONS CAUSED BY GRAM-NEGATIVE BACILLI , 2005 .

[25]  N. Caroff,et al.  AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. , 2003, The Journal of antimicrobial chemotherapy.

[26]  D. Yong,et al.  Evaluation of the Hodge Test and the Imipenem-EDTA Double-Disk Synergy Test for Differentiating Metallo-β-Lactamase-Producing Isolates of Pseudomonas spp. and Acinetobacter spp , 2003, Journal of Clinical Microbiology.

[27]  N. Woodford,et al.  Outbreak of Carbapenem-Resistant Acinetobacter baumannii Producing the OXA-23 Enzyme in Curitiba, Brazil , 2003, Journal of Clinical Microbiology.

[28]  M. Villegas,et al.  Acinetobacter Outbreaks, 1977–2000 , 2003, Infection Control & Hospital Epidemiology.

[29]  P. Nordmann,et al.  Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. , 2002, Current pharmaceutical biotechnology.

[30]  D. Livermore.  The impact of carbapenemases on antimicrobial development and therapy. , 2002, Current opinion in investigational drugs.

[31]  P. Gerner-Smidt,et al.  Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak , 1996, Journal of clinical microbiology.

[32]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.